Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28462887 | 0.95 | KDM4E (0.58) | L3MBTL1KDM4EALDH1A1GAAHTR1B | |
| SCHEMBL1760893 | 0.91 | L3MBTL1 (0.58) | L3MBTL1KDM4EALDH1A1GAAHTR1B | |
| SCHEMBL22221774 | 0.83 | L3MBTL1 (0.64) | L3MBTL1KDM4EALDH1A1GAAUSP2 | |
| SCHEMBL10778564 | 0.81 | L3MBTL1 (0.62) | L3MBTL1KDM4EALDH1A1GAAUSP2 | |
| SCHEMBL7199882 | 0.81 | L3MBTL1 (0.57) | L3MBTL1KDM4EALDH1A1GAAUSP2 | |
| SCHEMBL2429378 | 0.81 | L3MBTL1 (0.66) | L3MBTL1KDM4EALDH1A1GAAUSP2 | |
| SCHEMBL7199868 | 0.80 | L3MBTL1 (0.56) | L3MBTL1KDM4EALDH1A1GAAUSP2 | |
| SCHEMBL2097708 | 0.80 | L3MBTL1 (0.56) | L3MBTL1KDM4EALDH1A1GAAUSP2 | |
| SCHEMBL8188767 | 0.80 | L3MBTL1 (0.56) | L3MBTL1KDM4EALDH1A1GAAUSP2 | |
| SCHEMBL2097709 | 0.80 | L3MBTL1 (0.56) | L3MBTL1KDM4EALDH1A1GAAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602873-B2 | Angiogenesis inhibiting thiadiazolyl pyridazine derivatives | JANSSEN PHARAMACEUTICA, N.V. (BE) | 2003-08-05 | — | — | US | disclosed |
| EP-0991649-B1 | ANGIOGENESIS INHIBITING THIADIAZOLYL PYRIDAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2003-03-26 | — | — | EP | disclosed |
| US-20010046999-A1 | Angiogenesis inhibiting thiadiazolyl pyridazine derivatives | STOKBROEKX RAYMOND ANTOINE (BE) | 2001-11-29 | — | — | US | disclosed |
| US-6265407-B1 | WOUND HEALING AGENTS; ANTITUMOR AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010046999-A1 | Angiogenesis inhibiting thiadiazolyl pyridazine derivatives | KDR, TEK, TIE1 | L3MBTL1 3832/4885KDM4E 1502/4885ALDH1A1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.